Grace Capital’s ChemoCentryx, Inc. CCXI Stock Holding History

Grace Capital’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,500	Closed	-$155K	–	263
2020 Q4	$155K	Hold	2,500	–	–	0.1%	165
2020 Q3	$137K	Hold	2,500	–	–	0.11%	152
2020 Q2	$144K	Hold	2,500	–	–	0.12%	137
2020 Q1	$100K	Sell	2,500 -7,500	-75%	-$318K	0.1%	129
2019 Q4	$396K	Hold	10,000	–	–	0.32%	85
2019 Q3	$68K	Hold	10,000	–	–	0.07%	127
2019 Q2	$93K	Hold	10,000	–	–	0.04%	165
2019 Q1	$139K	Hold	10,000	–	–	0.05%	175
2018 Q4	$109K	Hold	10,000	–	–	0.05%	183
2018 Q3	$126K	Hold	10,000	–	–	0.05%	174
2018 Q2	$132K	Buy	+10,000	New	+$120K	0.05%	181

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Grace Capital's CCXI Position: Q1 2021 in Review

Grace Capital sold out of ChemoCentryx, Inc. (CCXI) in Q1 2021, closing a stake of 2,500 shares — an estimated $155K sold.

Grace Capital first reported a position in CCXI in Q2 2018 and held it in 11 quarters. The position peaked at $396K in Q4 2019. 183 funds tracked by Wall St. Rank hold CCXI as of Q1 2021.

Grace Capital reported no remaining ChemoCentryx, Inc. position as of Q1 2021 after selling out during the quarter.
Grace Capital sold 2,500 ChemoCentryx, Inc. shares in Q1 2021, an estimated $155K.
Grace Capital first reported a position in ChemoCentryx, Inc. in Q2 2018 and held it in 11 quarters.
Grace Capital's ChemoCentryx, Inc. position peaked at $396K in Q4 2019.
183 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2021.

Based on Grace Capital's 13F filing for Q1 2021, filed 6 May 2021.